Cagrilintide is a long-acting amylin analogue designed to mimic the physiological effects of the hormone amylin, which plays a key role in appetite regulation and metabolic control.
By activating amylin receptors, Cagrilintide has been extensively studied for its impact on satiety, gastric emptying, and energy intake reduction.
Originally developed for obesity and metabolic disorder research, Cagrilintide has demonstrated strong potential in reducing food intake and improving body weight regulation in preclinical and clinical investigations.
Researched Benefits:
- Facilitates analysis of amylin receptor-mediated appetite suppression
- Supports investigation into delayed gastric emptying and satiety signaling
- Enables studies on energy intake reduction and body weight regulation
- Useful for exploring synergistic effects with GLP-1 pathways
- Assists in modeling obesity and metabolic syndrome interventions
Description
Cagrilintide (50mg) is a research-grade peptide utilized in advanced metabolic and obesity-related studies. Manufactured with high-purity standards and precision synthesis, it is designed for consistency and reliability in laboratory applications.
Key Features:
- Long-acting amylin analogue for sustained receptor activity
- High-purity synthesis with rigorous quality control
- Batch-tested for consistency and reproducibility
- Lyophilized for enhanced stability and long-term storage
Applications:
- Investigates appetite regulation and satiety mechanisms
- Explores obesity treatment pathways and weight management models
- Supports research on metabolic disorders and energy balance
- Examines combination therapies (e.g., with GLP-1 analogues)
Cagrilintide is recognized in research for its potent effects on appetite suppression and metabolic regulation, offering valuable insights into next-generation anti-obesity therapies and energy balance mechanisms.
